BeiGene Ltd
(NAS:BGNE)
$
215
8.84 (4.29%)
Market Cap: 23.84 Bil
Enterprise Value: 22.24 Bil
PE Ratio: 0
PB Ratio: 6.64
GF Score: 81/100 Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023 / 01:20PM GMT
Release Date Price:
$209.24
(+8.62%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Okay. Thank you, everyone. Appreciate that. With that, happy to have with me Mr. Mehrdad Mobasher, CMO of Hematology from BeiGene; and Mark Lanasa, CMO of Solid Tumors for BeiGene. Thank you both for joining us.
Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology
Appreciate it.
Mark Lanasa
BeiGene, Ltd. - Senior VP & Chief Medical Officer for Solid Tumors
Appreciate it.
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Before we get into any pipeline-related and Brukinsa-related Q&A, I thought it might be good just to level set for the audience, if you could both just provide a quick overview of what you think some of the key inflection points have been across your respective areas of work at BeiGene for this year?
Mehrdad Mobasher
BeiGene, Ltd. - Chief Medical Officer of Hematology
So maybe I'll start first with
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot